Establishment of targeting therapy for hypopharyngeal cancer

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K16816
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Miyagi Prefectural Hospital Organization Miyagi Cancer Center
• Principal Investigator: Yamazaki Tomoko 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 特任研究員 (20792493)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 下咽頭がん

Outline of Final Research Achievements

Hypopharyngeal cancer is a refractory disease with few treatment options other than surgery. Our group has shown that CD271-positive cells have high proliferative and tumorigenic potential in hypopharyngeal carcinoma. Furthermore, we established a humanized anti-CD271 antibody. We performed antibody therapy targeting CD271 using PDX mice. We found that the tumor was decreased in the antibody-treated mice. However, the tumor reduction was not enough to apply clinical use, and further experimetns were reuired. The aim of this study is to present the proof of concept for CD271-targeted therapy. 1. We developed a new anti-CD271 antibody 2. We elucidated the mechanisms of CD271 transcription. 3. We attempted to generate CAR-NK cells.

Free Research Field

頭頸部内科

Academic Significance and Societal Importance of the Research Achievements

CD271が下咽頭がんにおける治療標的になる可能性を検討した。今後さらに治療応用に向けて検討を続ける必要がある。